80 percent of physicians preferred a meaningful, distinguishable suffix
WASHINGTON, DC – The Biologics Prescribers Collaborative, a project of the Alliance for Patient Access, released new findings from a poll of physicians conducted about the FDA’s proposed biosimilar naming guidelines. According to a SERMO poll representing physicians across multiple specialties, overwhelmingly, 80 percent of physicians preferred a meaningful four-letter suffix that noted the biosimilar manufacturer’s name, versus a random four-letter suffix. Only 8 percent of physicians preferred a suffix devoid of meaning while 12 percent had no preference.
More than half of physicians, 53 percent, said they would feel more confident prescribing a biosimilar if the product contained a meaningful suffix. Seven percent said they would feel more confident with a suffix devoid of meaning while 39 percent said it would have no impact on their confidence prescribing biosimilar products.
More than 2/3 of physicians were also interested in learning more about biosimilar clinical trial data.
The survey was conducted by SERMO, the largest global social network exclusively for doctors, October 11 and 12 with a sample size of 509. Rheumatologists and oncologists each accounted for 18 percent of respondents, with gastroenterologists at 17 percent, dermatologists and endocrinologists at 16 percent, and neurologists at 15 percent.
The medications’ four-letter suffixes, also known as “biological qualifiers,” differentiate their nonproprietary names, allowing physicians to accurately determine which biological medication a patient takes and to address any problems that might impact patient safety.
The FDA has not yet issued final guidance on naming conventions, despite continuing to approve applications for biosimilar medications. The agency has at different points in time endorsed both random and memorable suffix systems.
Originally, the FDA opted for a memorable suffix as a “placeholder” when approving the United States’ first biosimilar. The drug carries the name “filgrastim-sndz,” where the suffix “sndz” reflects the medication’s manufacturer, Sandoz. Nearly six months later, however, the agency released draft guidance indicating that it might deviate from its earlier approach and use randomly generated suffixes. In the biosimilar drug approvals that have followed, each has been assigned a random suffix.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.